drugset
drugset / Trial / NCT00200382

Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

NCT00200382 ↗

Phase 2 Terminated 27 enrolled Rasim Gucalp Millennium Pharmaceuticals, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.

Timeline

Start
2004-05
Primary completion
2007-05
Completion
2007-05

Outcome

Outcome not reported

Stopped: “The study did not achieve the statistical success to continue.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — —

Indications

non-small cell lung carcinoma